The Medicines Evaluation Board (MEB) is calling on marketing authorisation holders and companies to register alternatives for medicines on the Dutch market. This concerns medicines facing an anticipated long-term shortage or permanent discontinuation. The call applies to medicines that are essential for public health.
New registrations are required for the medicines listed below due to an actual or anticipated prolonged shortage.
| Date of call | Active substance |
Pharmaceutical form | Pharmaceutical strength |
| 2 April 2026 | lithium carbonate | tablet | 200 mg, 300 mg, 400 mg |
Marketing authorisation holders and companies are invited to contact the MEB if they wish to register medicines containing these active substances in the Netherlands. The MEB will work with applicants to determine the most appropriate regulatory pathway to bring the medicine to market.
This call relates specifically to new registrations for the Dutch market, not to the acquisition of an existing marketing authorisation.